Researchers looked back at medical records of 280 hospitalized adults who received the antibiotic tigecycline for serious infections caused by bacteria resistant to multiple drugs. These included infections from Acinetobacter baumannii, Escherichia coli, and Klebsiella pneumoniae. The study compared patients who received tigecycline alone to those who received it combined with other antibiotics.
Overall, just over half of patients (53.2%) achieved clinical success with treatment, and about one in four (26.1%) died within 30 days. At first glance, patients receiving tigecycline alone had a higher success rate (64.7%) than those on combination therapy. However, when researchers adjusted their analysis for how severely ill patients were and the type of infection, this advantage disappeared. Combination therapy was not independently linked to better success or lower mortality.
The main reason for caution is that this was a retrospective, single-center study. This means researchers looked at past records rather than assigning treatments randomly. Patients receiving combination therapy tended to be sicker to begin with, which could explain the initial difference. The authors also noted that tigecycline has known limitations for treating bloodstream and urinary tract infections, which affected their analysis. Readers should understand this is early, observational evidence from one hospital. The findings suggest that for these tough infections, how sick a patient is may matter more than whether they receive one antibiotic or two, but more research is needed to be sure.
